Comparative Pharmacology
Head-to-head clinical analysis: LOCHOLEST versus LOCHOLEST LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCHOLEST versus LOCHOLEST LIGHT.
LOCHOLEST vs LOCHOLEST LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Locholest is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting fecal excretion. This leads to increased hepatic conversion of cholesterol to bile acids, reducing serum LDL cholesterol.
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
Initial dose: 10-20 mg orally once daily, taken in the evening. Titrate as tolerated every 4 weeks to a maximum of 80 mg once daily.
LOCHOLEST LIGHT is not a recognized drug name. No data available.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 14-47 hours) for patients with normal renal function; accumulation occurs with once-daily dosing.
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Primarily fecal (biliary) as unchanged drug; renal excretion <5%.
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant